ProMIS Neurosciences Says PMN310 Alzheimer Drug Shows Positive Interim Safety, Biomarker Data

Data ReadoutpositivePMN310Positive

AI Analysis

Summary

ProMIS Neurosciences announced positive interim safety and biomarker data for PMN310, its Alzheimer's disease candidate. The specific trial phase, patient numbers, and complete details are not provided in the article.

Clinical Trial Data

Outcome Details

Positive interim safety and biomarker data

Importance:5/10

Sentiment:

0.60

Alzheimer's diseasePMN310safety databiomarker dataclinical trial

Related Companies

$PMN

Read the original article

Published by yahoo_finance on July 28, 2026 12:19 PM

Read Original